Zhonghua fu chan ke za zhi · 2007
[Retrospective study of chemoradiotherapy based on cisplatin compared with radiotherapy alone for cervical cancer].
Сравнительное исследованиеАннотация на английскомСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Han Chao, Kong Wei-min
Аннотация
OBJECTIVE: To compare the treatment effects and side events between chemoradiotherapy and radiotherapy alone for patients with primary cervical cancer.
METHODS: Totally 197 patients with primary cervical cancer in our hospital from 2000 to 2006 were studied. They were divided into two groups: radiotherapy alone (RT) or cisplatin-based chemoradiotherapy (CRT). Group of RT included 100 patients who received external irradiation by (60)Co and intracavitary irradiation by (192)Ir. Group of CRT included 97 patients who received cisplatin-based chemoradiotherapy. The RT regimen was the same as group RT.
RESULTS: The local control (CR + PR) in two groups had no statistic difference (P = 0.500). The total 5 year survival rate in the two groups were 82% and 79%, with no significant difference (P = 0.177); however, there was a significant difference for stage III squamous cell carcinoma of the cervix, the 5 year survival rate being 56% and 84%, respectively (P < 0.01). The common side effect was hematological toxicity in some patients, which was more serious in CRT group than in RT group. Grade 3 hematological toxicity were 3% and 14% (P < 0.01), although the long-term complications in two groups were not different (P = 0.496).
CONCLUSION: Chemoradiotherapy based on cisplatin may be effective for stage III squamous cell carcinoma of the cervix.
METHODS: Totally 197 patients with primary cervical cancer in our hospital from 2000 to 2006 were studied. They were divided into two groups: radiotherapy alone (RT) or cisplatin-based chemoradiotherapy (CRT). Group of RT included 100 patients who received external irradiation by (60)Co and intracavitary irradiation by (192)Ir. Group of CRT included 97 patients who received cisplatin-based chemoradiotherapy. The RT regimen was the same as group RT.
RESULTS: The local control (CR + PR) in two groups had no statistic difference (P = 0.500). The total 5 year survival rate in the two groups were 82% and 79%, with no significant difference (P = 0.177); however, there was a significant difference for stage III squamous cell carcinoma of the cervix, the 5 year survival rate being 56% and 84%, respectively (P < 0.01). The common side effect was hematological toxicity in some patients, which was more serious in CRT group than in RT group. Grade 3 hematological toxicity were 3% and 14% (P < 0.01), although the long-term complications in two groups were not different (P = 0.496).
CONCLUSION: Chemoradiotherapy based on cisplatin may be effective for stage III squamous cell carcinoma of the cervix.